Skip Navigation

This Article
Right arrow Abstract Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Disclaimer
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Sleight, P.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Sleight, P.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?


The renin-angiotensin system: a review of trials with angiotensin-converting enzyme inhibitors and angiotensin receptor blocking agents

P. Sleight*

Department of Cardiovascular Medicine, University of Oxford, John Radcliffe Hospital, Oxford, U.K.

* Correspondence: Peter Sleight, Honorary Consultant Physician, Professor Emeritus of Cardiovascular Medicine, University of Oxford, John Radcliffe Hospital, Oxford OX3 9DU, U.K.

Abstract

Angiotensin-converting enzyme (ACE) inhibitors have been very successful in patients with vascular disease, in particular for hypertension, left ventricular dysfunction and vascular protection. Angiotensin receptor blocking drugs (ARBs) were developed later and differ from ACE inhibitors in several ways. We are now beginning to see the results of large studies of ARBs in high-risk patients and some head-to-head comparisons between these two classes of drugs which reduce the actions of angiotensin H. This review considers these trials under the headings of heart failure, hypertension, renal function, and high-risk cardiovascular disease/coronary heart disease.

Key Words: Hypertension • left ventricular dysfunction • left ventricular hypertrophy • myocardial infarction • heart failure • cough • endothelium • plaque rupture

References

  1. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet. 1993;342:821–828[Web of Science][Medline]
  2. GISSI-3 (Gruppo Italiano per to Studio della Sueptochinasi nell'Infarcto Miocardico). GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after myocardial infarction. Lancet. 1994;343:1115–1121[Web of Science][Medline]
  3. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. ISIS-4: a randomised trial comparing oral captopril versus placebo, oral mononitrate versus placebo, and intravenous magnesium sulphate versus control among 58,050 patients with suspected acute myocardial infarction. Lancet. 1995;345:669–687[CrossRef][Web of Science][Medline]
  4. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting enzyme inhibitor, ramipril, on death from cardiovascular causes, myocardial infarction, and stroke in high-risk patients. N Engl J Med. 2000;342:145–153[Abstract/Free Full Text]
  5. Sleight P, Yusuf S, Pogue J, Tsuyuki R, Diaz R, Probstfield J. Ramipril in the HOPE Study reduces risk independently of entry blood pressures or fall with treatment. for the Heart Outcomes Protection Evaluation (HOPE) Study InvestigatorsLancet Res Lett. 2001;: in press
  6. Otterstad JE, Sleight P. The HOPE study: comparison with other trials of secondary prevention. Eur Heart J. 2000;22:1307–1310
  7. Mathew J, Sleight P, Lonn E, et al. Reduction of cardiovascular risk by regression of electrocardiographic markers of left ventricular hypertrophy by the angiotensin converting enzyme inhibitor, ramipril. Circulation. 2001;104:1615–1621[Abstract/Free Full Text]
  8. Davies MJ. Reactive oxygen species, metalloproteinases, and plaque stability. Circulation. 1998;92:2382–2383
  9. Balcells E, Meng QC, Johnson WH, Paril S, Dell'Italia LJ. Angiotensin II formation from ACE and chymase in human and animal hearts: methods and species considerations. Am J Physiol. 1997;273:H1769–H1774
  10. Pitt B, Segal R, Martinez FA, et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet. 1997;349:747–752[CrossRef][Web of Science][Medline]
  11. Pitt B, Poole-Wilson P, Segal R, et al. Effects of losartan versus captopril on mortality in patients with symptomatic heart failure: rationale, design, and baseline characteristic of patients in the Losartan Heart Failure Survival Study - ELITE II. J Card Fail. 1999;5:146–154[CrossRef][Web of Science][Medline]
  12. McKelvie RS, Yusuf S, Pericak D, et al. (The RESOLVD Pilot Study Investigators). Comparison of candesartan, enalapril, and their combination in congestive heart faislure. Randomized Evaluation of Strategies for Left Ventricular Dysfunction (RESOLVD) Pilot Study. Circulation. 1999;100:1056–1064[Abstract/Free Full Text]
  13. Martineau P, Goulet J. New competition in the realm of renin-angiotensin axis inhibition; the angiotensin II receptor antagonists in congestive heart failure. Ann Pharmacother. 2001;35:71–84[Abstract]
  14. Parving H-H, Lehnert H, Brner-Mogensen J, Gomis R, Andersen S, Arner P. The effects of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. for the Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study GroupN Engl J Med. 2001;345:870–878[Abstract/Free Full Text]
  15. Lewis EJ, Hunsicker LG, Clarke WR, et althe Collaborative Study Group. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345:851–860[Abstract/Free Full Text]
  16. Brenner BM, Cooper ME, de Zeeuw D, et al, the RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345:861–869[Abstract/Free Full Text]
  17. Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet. 2000;355:253–259[CrossRef][Web of Science][Medline]
  18. Mann JFE, Gerstein HC, Pogue J, Bosch J, Yusuf S, the HOPE Investigators. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Ann Intern Med. 2001;234:629–636
  19. Lonn E, Yusuf S, Dzavik V, et al. Effects of ramipril and vitamin E on atherosclerosis: the study to evaluate carotid ultrasound changes in patients treated with ramipril and vitamin E (SECURE). Circulation. 2001;103:919–925[Abstract/Free Full Text]
  20. Sun YP, Zhu BQ, Browne AE, et al. Comparative effects of ACE inhibitors and an angiotensin receptor blocker on atherosclerosis and vascular function. J Cardiovasc Pharmacol Ther. 2001;6:175–181[Abstract/Free Full Text]
  21. Andersen NH, Mogensen CE. Inhibition of the renin-angiotensin system, with particular reference to dual blockade treatment. J RAAS. 2001;2:146–152
  22. Swedberg K, Pfeffer M, Granger C, et al, the CHARM-Programme Investigators. Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM): rationale and design. J Card Fail. 1999;5:276–282[CrossRef][Medline]
  23. Unger T. Pharmacological properties of angiotensin-II antagonists: examining all the therapeutic implications. J RAAS. 2001;2(suppl 2):S4–S7

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?



This Article
Right arrow Abstract Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Disclaimer
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Sleight, P.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Sleight, P.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?